

Comparative Effectiveness of Mannitol versus Hypertonic Saline in Traumatic Brain Injury patients: a CENTER-TBI study

Ernest van Veen^{1,2}, BSc, Daan Nieboer², PhD, Erwin J. O. Kompanje^{1,3}, PhD, Giuseppe Citerio^{4,5}, MD, Nino Stocchetti^{6,7}, MD, Diederik Gommers¹, MD, David K. Menon⁴, MD, Ari Ercole⁴, MD, Andrew I. R. Maas⁹, MD, Hester F. Lingsma², PhD, Mathieu van der Jagt¹, MD, and the CENTER-TBI investigators and participants*

¹ Department of Intensive Care Adults, Erasmus MC - University Medical Center, Rotterdam, the Netherlands. ² Department of Public Health, Erasmus University Medical Center, Rotterdam, the Netherlands. ³ Department of Medical Ethics and Philosophy of Medicine, Erasmus University Medical Center, Rotterdam, the Netherlands. ⁴ School of Medicine and Surgery, University of Milan-Bicocca, Milan, Italy. ⁵ San Gerardo Hospital, ASST-Monza, Italy. ⁶ Department of Physiopathology and Transplantation, Milan University, Milan, Italy. ⁷ Neuro ICU Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico Milano, Milan, Italy. ⁸ Department of Anaesthesia, University of Cambridge, Cambridge, United Kingdom. ⁹ Department of Neurosurgery, Antwerp University Hospital and University of Antwerp, Edegem, Belgium. * Listed at the end of the manuscript.

Ernest van Veen, corresponding author:	e.vanveen.1@erasmusmc.nl , +31 10 70 38 460
Daan Nieboer:	d.nieboer@erasmusmc.nl , +31 10 70 38 460
Erwin Kompanje:	e.j.o.kompanje@erasmusmc.nl , +31 10 70 38 460
Giuseppe Citerio:	giuseppe.citerio@unimib.it , +31 10 70 38 460

Nino Stocchetti: nino.stocchetti@policlinico.mi.it,

+31 10 70 38 460

Diederik Gommers

d.gommers@erasmusmc.nl,

+31 10 70 38 460

David K. Menon:

dkm13@cam.ac.uk,

+31 10 70 38 460

Ari Ercole:

ae105@cam.ac.uk,

+31 10 70 38 460

Andrew Maas:

andrew.Maas@uza.be,

+31 10 70 38 460

Hester Lingsma:

h.lingsma@erasmusmc.nl,

+31 10 70 38 460

Mathieu van der Jagt:

m.vanderjagt@erasmusmc.nl,

+31 10 70 38 460

CENTER-TBI investigators and participants:

e.vanveen.1@erasmusmc.nl,

+31 10 70 38 460

Corresponding author:

Ernest van Veen

Erasmus MC University Medical Center

Department of Public Health

P.O. Box 2040

3000 CA Rotterdam

The Netherlands

e.vanveen.1@erasmusmc.nl

Keywords: Traumatic brain injury, critical care, intensive care unit, osmolar therapy

Preprint server

This paper has been previously submitted to Research Square and can be located here:

<https://www.researchsquare.com/article/rs-1958486/v1>

<https://doi.org/10.21203/rs.3.rs-1958486/v1>

ABSTRACT

Introduction: Increased intracranial pressure (ICP) is one of the most important modifiable and immediate threats to critically ill patients suffering from traumatic brain injury (TBI). Two hyperosmolar agents (HOA), mannitol and hypertonic saline (HTS) are routinely used in clinical practice to treat increased ICP. We aimed to assess whether a preference for mannitol, HTS or their combined use translated into differences in outcome.

Methods: The CENTER-TBI Study is a prospective multicenter cohort study. For this study, patients with TBI, admitted to the ICU, treated with mannitol and/or HTS, aged ≥ 16 , were included. Patients and centers were differentiated based on treatment preference with mannitol and/or HTS based on structured, data-driven criteria such as first administered HOA in the ICU. We assessed influence of center and patient characteristics in the choice of agent using adjusted multivariate models. Furthermore, we assessed the influence of HOA preference on outcome using adjusted ordinal and logistic regression models, and instrumental variable analyses.

Results: In total, 2056 patients were assessed. Of these, 502 (24%) patients received mannitol and/or HTS in the ICU. The first received HOA was HTS for 287 (57%) patients, mannitol for 149 (30%) patients, or both mannitol and HTS on the same day for 66 (13%) patients. Two unreactive pupils were more common for patients receiving both (13, 21%), compared to patients receiving HTS (40, 14%), or mannitol (22, 16%). Center, rather than patient characteristics, was independently associated with the preferred choice of HOA (p -value < 0.05). ICU mortality and 6-month outcome were similar between patients preferably treated with mannitol compared to HTS (OR = 1.0, CI = 0.4 – 2.2; OR = 0.9, CI = 0.5 – 1.6 respectively). Patients who received both also had a similar ICU mortality and 6-month outcome compared to patients receiving HTS (OR = 1.8, CI = 0.7 – 5.0; OR = 0.6, CI = 0.3 – 1.7 respectively).

Conclusion: We found between center variability regarding HOA preference. Moreover, we found that center is a more important driver of the choice of HOA than patient characteristics. However, our study indicates that this variability is an acceptable practice given absence of differences in outcomes associated with a specific HOA.

Keywords: Traumatic brain injury, critical care, intensive care unit, osmolar therapy

INTRODUCTION

Intracranial hypertension (IH), or elevated intracranial pressure (ICP > 20-25mmHg),¹ is one of the most important immediate threats to critically ill patients with traumatic brain injury (TBI). IH contributes to secondary brain injury but is modifiable with various treatments, including hyperosmolar agents (HOAs).² Two HOAs, mannitol and hypertonic saline (HTS), are routinely used in clinical practice to decrease ICP.¹⁻⁶

Consensus guidelines have not stated a clear preference for one of the HOAs,^{1,2,5,6} since systematic reviews and meta-analyses were inconclusive or yielded contradictory findings both in effects on ICP and clinical outcomes, and since there is a dearth of adequately powered randomized clinical trials.⁷⁻¹⁶ Therefore, it is likely that centers and clinicians balance potential benefits and risks based on their personal experiences with HOA,¹⁷ but it is unclear whether such variability ultimately results in differences in outcome.¹⁸

When randomized controlled trials (RCTs) of sufficient size and quality are unfeasible or unavailable, between center differences in policies can be leveraged to study policy-outcome relations in observational data using comparative effectiveness research. Therefore, we aimed to assess the use of and effect on outcome of mannitol versus HTS by: 1) studying the influence of baseline characteristics versus center-effect on the choice of HOA, and: 2) assessing whether a preference for mannitol, HTS or their combined use translated into differences in outcome.

METHODS

Study population

The Collaborative European NeuroTrauma Effectiveness Research in TBI (CENTER-TBI, registered at clinicaltrials.gov NCT02210221) study is a prospective cohort study conducted in 63 centers from 18 countries across Europe and Israel between 2014 and 2017. Patients were included if they arrived at the hospital within 24 hours after injury with a clinical diagnosis of TBI and had an indication for a head computed tomography (CT) scan. Patients were excluded if they had a severe pre-existing neurological disorder that

would confound outcome assessment. Ethics approval was acquired for each center and consent for participation obtained from all patients or their proxies. For more information on the CENTER-TBI study, see previous publications.^{19,20} For this study, we selected patients aged 16 or older who were admitted to the ICU. For further analyses of HOA, we only included patients who were treated with mannitol and/or HTS during their ICU stay, and we extracted data on demographics, country, center, injury, admission, imaging, monitoring, treatment, and outcome characteristics. Moreover, we used data of the CENTER-TBI study on reported practices regarding HOA use. In an earlier publication from Cnossen et al.,²¹ detailed information about the development, administration, and content of these provider profilings is available.²¹

Outcomes

First, we aimed to assess the influence of center on HOA preference: mannitol, HTS, or both.

Second, we aimed to assess the association between the preference for a HOA on outcomes, defined as ICU mortality and the Glasgow Outcome Scale-Extended (GOSE), assessed at 6 months after injury. GOSE is an eight-point outcome scale that captures outcome. Category 2 and 3 were combined, resulting in a seven-point ordinal scale.

Data collection

Definitions of preferences for mannitol, HTS or the use of both

In the electronic case report form (e-CRF), administration of mannitol, HTS, neither, or both HOAs was scored on a daily level (received: yes/no). To overcome the lack of data on dosages of mannitol and HTS in the e-CRF, the preference for mannitol, HTS, or both was captured in five post-hoc constructed variables, namely:

1. Preference on *patient-level*: we designated a patient as a 'HTS-patient' if the patient received HTS as their first HOA in the ICU, even if the patient would receive mannitol on subsequent days. We applied the same rule for mannitol and the patient could also be noted as having received both agents.
2. Preference on *center-level*: if more than two-thirds (>66%) of patients in a center

were regarded as ‘HTS-patients’ on *patient-level*, we designated this center as a ‘HTS-center’, and patients were considered treated with HTS, even if some received mannitol on other occasions. We applied the same rule for mannitol. To test robustness of this definition, sensitivity analyses were done using 75% instead of 66% as cut-off value. When the proportion was less than two-thirds (and in the sensitivity analyses less than 75%), this unit of analysis was designated as ‘center preference for using both HOA’.

3. Preference on *management-level*: investigators in all centers indicated their preferred agent in a previous provider profiling analysis, published by Crossen et al.¹⁷ In this previous provider profiling, investigators of a center could indicate their preferred HOA.¹⁷ If the investigators in a center indicated that HTS was their preferred HOA, then all patients in this hospital would be regarded as HTS patients, vice-versa for mannitol, and both.
4. Preference using the *patient-HTS sum score*: this unit for analysis is defined as the number of times a patient received HTS divided by the total number of times a patient received any HOA. When a patient received both mannitol and HTS on one day, this patient would score ‘2’ for this day instead of ‘1’ when only receiving mannitol or HTS.
5. Preference using the *center-HTS sum score*: defined as the total of the sum score of all patients, divided by the number of patients in that center.

Statistical analyses

Baseline characteristics

Baseline characteristics were presented as median values with interquartile ranges (IQRs) for continuous variables and as frequencies and percentages for categorical variables. We compared characteristics between patients who did not receive a HOA, and patients who did receive a HOA, and between patients who received mannitol, HTS, or both mannitol and HTS on the same day. To test for differences between these groups, we used the

Pearson χ^2 test for categorical variables and the independent t-test or Mann–Whitney U-Test for continuous variables.

Baseline variables

We collapsed category 3 and 4 of the American Society of Anesthesiologists (ASA) Physical Status classification because category 4 had <10 patients. We collapsed category V and VI of the Marshall CT classification as grading V and VI could not be differentiated on central review as the raters were not aware of (intent to) surgery. Last, to compare groups at baseline we calculated the expected probability of mortality and unfavourable outcome using the IMPACT core prediction model.²² We defined unfavourable outcome as a GOSE <5.

Association of center with HOA preference

To assess the effect of center on the HOA preference, two multivariate regression models were compared using the likelihood ratio test. We compared two multivariate model with a binary dependent variable (mannitol versus HTS). One model had a random intercept on patient level, whereas the other model had a random intercept on patient *and* center level. Both models were adjusted for baseline characteristics (age, GCS motor score, pupillary reactivity, and major extracranial injury (MEI), and Marshall CT score).

A significant likelihood ratio test indicates an association of the independent variable that is present in one model, and absent in the other. In this case, a significant likelihood ratio test indicates that the choice to administer mannitol or HTS is not based on baseline characteristics, but on the center to which the patient is admitted, indicating random practice variation.

Association of HOA with outcome

We used ordinal and logistic regression to assess associations between the HOA preference and the outcome. Given the observational nature of the data, we used different approaches to assess the reproducibility and robustness of the association of HOAs with ICU mortality and GOSE. Logistic regression was performed for ICU mortality. Ordinal regression was performed for GOSE. The statistical analyses were performed

separately for every post-hoc variable indicating HOA preference. All models were tested univariably, and multivariably. In the multivariable analyses, we first adjusted for baseline characteristics (age, GCS motor score, pupillary reactivity, MEI, and Marshall CT classification). Subsequently, we adjusted for the baseline characteristics and additional treatment characteristics (mean ICP before receiving a HOA, mean therapy intensity level (TIL) before receiving a HOA, and median daily fluid balance during the whole ICU stay). We included a random intercept for center in all multivariable models to adjust for center characteristics (differences in patient population, other management aspects) that could confound the estimated association between center preference for HTS/mannitol and outcome.²³

To overcome unmeasured confounding, instrumental variable (IV) analyses is suggested²⁴. We used the following post-hoc variables as our instrument for the IV analyses: '*preference on center-level*', '*preference on management-level*', and '*center-HTS sum score*'.

Associations for ICU mortality and GOSE were expressed as Odds Ratios (ORs) with 95% confidence intervals (CIs). An OR above 1 indicates *worse* outcome for ICU mortality, but *better* outcome for GOSE.

All statistical analyses were performed in R studio.²⁵ Multiple imputation was used to handle missing values, with use of the mice package in R.²⁶ Data were accessed using a bespoke data management tool, 'Neurobot' (neurobot.incf.org), version 3.0 (data freeze: March 2021).

RESULTS

Baseline characteristics

We assessed 2056 patients aged 16 or older, admitted to the ICU. Of these, 502 patients (24%) received a HOA during ICU stay. Patients receiving HOAs were younger, had more severe brain injury on admission, received more ICP lowering treatments and had longer hospital length of stay and worse outcome (p-values < 0.001). The mean ICP during ICU stay was 13.5 mmHg (IQR = 10.7 – 16.9) for patients receiving HOAs versus 9.7 mmHg (IQR

= 7.1 – 12.5) for those without (p -value < 0.001). In total, 110 patients (22%) who received a HOA died in the ICU versus 160 (10.4%) patients who did not receive a HOA (p -value < 0.001) (Additional file 1).

In the HOA group, we found a preference for HTS in 287 (57%) patients, mannitol for 149 (30%) patients, and use of both agents for 66 (13%) patients. An overview of the percentage of patients per center, can be found in Figure 1. The median age in the mannitol group was higher (49 years) than for patients receiving HTS or both (42 and 43 years respectively) (p -value 0.04). In the HTS group, 125 (45%) patients had a GCS motor score of 1, compared to 71 (48%) patients in the mannitol group, and 28 (44%) patients receiving both. Two unreactive pupils were more common for patients receiving both (13, 21%), compared to patients receiving HTS (40, 14%), or mannitol (22, 16%). Similarly, more patients receiving both agents, had a MEI (43, 65%), compared to patients receiving HTS (153, 53%), or mannitol (87, 58%). None of these findings were statistically significant (p -values of 0.255, 0.185 and 0.182 respectively) (Table 1).

The mean ICP during ICU stay was 13.2 mmHg (IQR = 10.2 – 16.2) for the HTS group, 13.3 mmHg (IQR = 10.9 – 16.6) for the mannitol group, and 15.3 mmHg (IQR = 12.5 – 20.7) for patients receiving both (p -value 0.001). The mean ICP before receiving an agent was 13.6 mmHg (IQR = 9.8 – 16.7) for the HTS group, 13.5 mmHg (IQR = 11.1 – 17) for the mannitol group and 16.1 mmHg (IQR = 12.8 – 22.7) for patients receiving both (p -value 0.002). The median of the maximum TIL before receiving an agent was higher for patients receiving both agents (15, IQR = 12.3 – 19), compared to the HTS group (11, IQR = 8 – 14), and the mannitol group (11, IQR = 8 – 15) (p -value < 0.001) (Table 1).

Center effect on HOA preference

We compared one model with center as random intercept to one model without center as random intercept. We adjusted for baseline characteristics. The model with center as random intercept was significant with a p -value of < 0.05 .

Association of HOA preference with outcome

In the HTS group, 58 (20%) patients did not survive their ICU stay compared to 28 (19%) patients in the mannitol group, and 24 (36%) patients in the group receiving both HOAs (Table 1). In multivariable analyses, after adjustment for baseline characteristics, there were no differences in probability of mortality between the mannitol and HTS group in the *patient-level* analysis (OR = 0.94, CI = 0.51 – 1.71). After additional adjustment for treatment characteristics, no differences in probability of mortality were found between the mannitol and HTS group in the *patient-level* analysis (OR = 0.98, CI = 0.44 – 2.20). Similar observations were found on all levels (Table 2).

In the HTS group, 154 (61%) patients had an unfavourable outcome after 6 months compared to 82 (62%) patients in the mannitol group, and 48 (77%) patients in the group receiving both HOAs (Table 1). In multivariable analyses, after adjustment for patient and treatment characteristics, there were no differences in probability of unfavourable outcome between the mannitol and HTS group in the *patient-level* analysis (OR = 0.91, CI = 0.53 – 1.58). Similar observations were found on all levels (Table 3).

Missing data

The percentage of missing data used in the imputed models varied between 0% and 20%. There was no missing data on age, sex, MEI. GCS motor score was missing in 2.2% of patients, pupillary reactivity at baseline in 6.6% of patients, Marshall CT classification had 11.4% missingness, fluid balance was missing in 12.5% of patients, and mean ICP before receiving mannitol or HTS in 14% of the patients. The outcome, GOSE, was missing in 10.6% of patients.

DISCUSSION

In this study, we found that the preference for HOA in ICUs across European trauma centers varied. This variation was driven by center rather than patient characteristics indicating random between center variability, based on local preferences. This circumstance facilitated comparative effectiveness analysis on a patient-level, center-level, and management-level, which showed that the choice for a specific HOA was not

associated with higher ICU mortality or worse 6-month outcome after extensive statistical adjustments for possible confounding factors.

In a recent comparative effectiveness study, effects of bolus HTS versus mannitol were assessed in a pediatric population and the results of this analysis in 521 children showed similar effects on cerebral perfusion pressure and possibly better effect of HTS compared with mannitol on immediate post bolus ICP. This finding is in line with current practice guidelines in pediatric TBI patients favoring HTS over mannitol and shows the robustness of this type of analyses to underpin clinical practice guidelines.²⁷ Our analysis was different and focused on clinical outcomes, associated with the preference for one of the HOAs and likewise seems to underpin current practices and guidelines that do not favor one HOA over the other. Contrary to our findings, Anstey et al.²⁸ found that patients who received mannitol compared to patients who received HTS had a higher Marshall CT score, a higher ISS and had a higher predicted probability of 6-month mortality using the extended IMPACT score.²⁸ However, when comparing patients who received mannitol or HTS to the patients who received both, we found that patients who received both, had higher ICP during their ICU stay, and had a higher maximum TIL. The worse outcome associated with the higher TIL in univariable analysis can be explained, since clinicians will apply more intense treatment regimens in patients with more severe brain injury. This indicates *confounding by indication*. To overcome confounding by indication, multivariable analyses and instrumental variable (IV) analyses have been suggested,²⁴ and both were applied in this study. Using these analyses, we could not detect differences in outcome depending on the choice of HOA. We performed IV analyses on center-level and on management-level. The IV analyses on center-level represent the clinical choices of the specific center based on prospective clinical data. However, the IV analyses on center-level can still be clouded by case-mix, since the IV was derived from the core data. This is not the case when performing the IV analyses on management-level, since this data was not derived from the core data, but from previously collected data. The robustness of our results was supported by using different definitions of HOA preference at center, patient, and management level, and various methodological approaches, yielding consistent results after statistical adjustment for possible confounders.

Variable results of comparisons between mannitol and HTS in TBI patients were found in previous systematic reviews and meta-analyses.^{7-16,29} The studies reporting outcomes, did not show any differences.^{12,13,15,16} A separate “umbrella review”, summarizing the findings of previous meta-analyses, is being drafted by Badenes et al.³⁰ Therefore, our findings are in line with previous research and consolidate the notion of lack of superiority of using one agent over the other. Future intervention trials, such as the “Sugar or Salt Trial”,³¹ comparing mannitol and hypertonic saline may shed more light on the risk versus benefit of both agents, especially regarding ease of use and possible side effects.³¹

Given the similar outcomes for mannitol and HTS patients in this and previous studies, the occurrence and the seriousness of adverse events may be important for the choice of a HOA. Previous studies found that high dose mannitol can cause acute renal failure,³² electrolyte abnormalities,^{33,34} acidosis,³⁴ hypotension,^{33,35,36} and congestive heart failure with pulmonary edema.³⁷ A recent study found that a quarter of patients who received mannitol in the first three days after admission in the ICU, developed AKI compared to more than one third of patients who received HTS.³⁸ The hazard ratio (HR), after adjustment for the IMPACT extended score²², for developing AKI when mannitol was administered compared to when mannitol was not, was 2.13 (CI from 1.38 to 3.30).³⁸ The HR for HTS was 1.5 (CI from 0.98 to 2.21).³⁸ Thus, administering HTS rather than mannitol is associated with a lower risk for the development of AKI during ICU stay after TBI.³⁸

Following the guidelines of the Neurocritical Care Society, clinicians should monitor intravascular volume status, renal function, and serum osmolality closely when using mannitol,⁶ and, when using HTS, hypernatremia and hyperchloremia, and acid–base balance deserve closer attention.⁶

The CENTER-TBI study is unique for its extensive and prospective data collection in multiple centers, enrolling TBI patients with varying injury severity across a wide range of European centers. However, this study also has limitations which should be considered when interpreting the results. First, all centers participating in CENTER-TBI are characterized by their commitment to TBI research. They might represent a selected

sample of the neurotrauma centers in Europe limiting generalizability. Second, receiving mannitol and/or HTS was indicated once per day and as either present or absent, limiting assessment of dose-response relations. Third, we had no insight in detailed information on or specific indications for the use of either mannitol and/or HTS. For example, some centers may use mannitol to treat herniation events, but use HTS as a first line approach to treat elevated ICP, or the other way around. This could lead to unmeasured confounding. However, our 5 definitions to define HOA preference were meant to effectively circumvent this form of confounding. Furthermore, we accounted for potential unmeasured confounding by using IV analyses, on center and management level, concluding that there was no difference in outcome when using HTS compared to mannitol. Last, due to the limitations in the granularity of the dataset, we were not able to investigate safety profiles for mannitol and/or HTS.

Future studies, preferably a large RCT such as the “Sugar or Salt Trial”,³¹ should look more closely at effects of equimolar dosages of mannitol and HTS. If future ongoing RCTs also point to the direction of similar outcomes between mannitol and HTS, safety profiles and cost-effectiveness may become a more important factor in clinicians’ preference. Further, efficacy research may be facilitated when patient characteristics can be identified that are associated with either improved effect of a specific agent or less complications and better safety profile to target HOA to specific clinical characteristics which may improve personalized choices.

CONCLUSION

There is a large variation between centers in the use of either mannitol, HTS, or both. Center is a more important driver for the choice of HOA than patient characteristics, indicating random practice variation. We found no differences in outcome associated with variability in HOA preferences in this comparative effectiveness study. Our results support that the current variation in use of different HOA is an acceptable clinical practice. However, the complexities in this analysis argue against oversimplification of study questions for future research assessing superiority of one agent over the other, without accounting for other concomitant components of local treatment policies.

ABBREVIATIONS

ASAPS = American Society of Anesthesiologists Physical Status; CT = Computed tomography; DC = decompressive craniectomy; GCS = Glasgow coma scale; GOSE = Glasgow outcome scale extended; HTS = hypertonic saline; ICP = intracranial pressure; ICU = intensive care unit; IQR = interquartile range; ISS = injury severity score; TIL = therapy intensity level

DECLARATIONS

Ethics approval and consent to participate

The Medical Ethics Committees of all participating centers approved the CENTER-TBI study, and informed consent was obtained according to local regulations

Consent for publication

Not applicable

Availability of data and materials

The data supporting the findings in the study are available upon reasonable request from the corresponding Author (EvV) and are stored at <https://center-tbi.incf.org/>

Conflicts of Interest

GC is Editor-in-Chief of Intensive Care Medicine. GC reports grants, personal fees as Speakers' Bureau Member and Advisory Board Member from Integra and Neuroptics; personal fees from Nestle and UCB Pharma, all outside of the submitted work.

DKM reports grants from the European Union and UK National Institute for Health Research, during the conduct of the study; grants, personal fees, and non-financial support from GlaxoSmithKline; personal fees from Neurotrauma Sciences, Lantmaanen AB, Pressura, and Pfizer, outside of the submitted work. The other authors declare that they have no competing interests.

Funding

Data used in preparation of this manuscript were obtained in the context of CENTER-TBI, a large collaborative project, supported by the Framework 7 program of the European Union (602150). The funder had no role in the design of the study, the collection, analysis, and interpretation of data, or in writing the manuscript.

David K. Menon was supported by a Senior Investigator Award from the National Institute for Health Research (UK). The funder had no role in the design of the study, the collection, analysis, and interpretation of data, or in writing the manuscript.

Authors' contributions

EvV analyzed the data and drafted the manuscript, and the supplementary tables and figures. All coauthors gave feedback on the manuscript. MvdJ supervised the project. All coauthors gave feedback on (and approved) the final version of the manuscript.

CENTER-TBI INVESTIGATORS AND PARTICIPANTS

Cecilia Åkerlund¹, Krisztina Amrein², Nada Andelic³, Lasse Andreassen⁴, Audny Anke⁵, Anna Antoni⁶, Gérard Audibert⁷, Philippe Azouvi⁸, Maria Luisa Azzolini⁹, Ronald Bartels¹⁰, Pál Barzó¹¹, Romuald Beauvais¹², Ronny Beer¹³, Bo-Michael Bellander¹⁴, Antonio Belli¹⁵, Habib Benali¹⁶, Maurizio Berardino¹⁷, Luigi Beretta⁹, Morten Blaabjerg¹⁸, Peter Bragge¹⁹, Alexandra Brazinova²⁰, Vibeke Brinck²¹, Joanne Brooker²², Camilla Brorsson²³, Andras Buki²⁴, Monika Bullinger²⁵, Manuel Cabeleira²⁶, Alessio Caccioppola²⁷, Emiliana Calappi²⁷, Maria Rosa Calvi⁹, Peter Cameron²⁸, Guillermo Carbayo Lozano²⁹, Marco Carbonara²⁷, Simona Cavallo¹⁷, Giorgio Chevallard³⁰, Arturo Chierigato³⁰, Giuseppe Citerio^{31, 32}, Hans Clusmann³³, Mark Coburn³⁴, Jonathan Coles³⁵, Jamie D. Cooper³⁶, Marta Correia³⁷, Amra Čović³⁸, Nicola Curry³⁹, Endre Czeiter²⁴, Marek Czosnyka²⁶, Claire Dahyot Fizelier⁴⁰, Paul Dark⁴¹, Helen Dawes⁴², Véronique De Keyser⁴³, Vincent Degos¹⁶, Francesco Della Corte⁴⁴, Hugo den Boogert¹⁰, Bart Depreitere⁴⁵, Đula Đilvesi⁴⁶, Abhishek Dixit⁴⁷, Emma Donoghue²², Jens Dreier⁴⁸, Guy Loup Dulière⁴⁹, Ari Ercole⁴⁷, Patrick Esser⁴², Erzsébet Ezer⁵⁰, Martin Fabricius⁵¹, Valery L. Feigin⁵², Kelly Foks⁵³, Shirin Frisvold⁵⁴, Alex Furmanov⁵⁵, Pablo Gagliardo⁵⁶, Damien Galanaud¹⁶, Dashiell Gantner²⁸, Guoyi Gao⁵⁷, Pradeep George⁵⁸, Alexandre Ghuysen⁵⁹, Lelde Giga⁶⁰, Ben

Glocker61, Jagoš Golubovic46, Pedro A. Gomez 62, Johannes Gratz63, Benjamin Gravesteijn64, Francesca Grossi44, Russell L. Gruen65, Deepak Gupta66, Juanita A. Haagsma64, Iain Haitsma67, Raimund Helbok13, Eirik Helseth68, Lindsay Horton 69, Jilske Huijben64, Peter J. Hutchinson70, Bram Jacobs71, Stefan Jankowski72, Mike Jarrett21, Ji yao Jiang58, Faye Johnson73, Kelly Jones52, Mladen Karan46, Angelos G. Koliass70, Erwin Kompanje74, Daniel Kondziella51, Evgenios Kornaropoulos47, Lars Owe Koskinen75, Noémi Kovács76, Ana Kowark77, Alfonso Lagares62, Linda Lanyon58, Steven Laureys78, Fiona Lecky79, 80, Didier Ledoux78, Rolf Lefering81, Valerie Legrand82, Aurelie Lejeune83, Leon Levi84, Roger Lightfoot85, Hester Lingsma64, Andrew I.R. Maas43, Ana M. Castaño León62, Marc Maegeler86, Marek Majdan20, Alex Manara87, Geoffrey Manley88, Costanza Martino89, Hugues Maréchal49, Julia Mattern90, Catherine McMahon91, Béla Meleghe92, David Menon47, Tomas Menovsky43, Ana Mikolic64, Benoit Misset78, Visakh Muraleedharan58, Lynnette Murray28, Ancuta Negru93, David Nelson1, Virginia Newcombe47, Daan Nieboer64, József Nyirádi2, Otesile Olubukola79, Matej Oresic94, Fabrizio Ortolano27, Aarno Palotie95, 96, 97, Paul M. Parizel98, Jean François Payen99, Natascha Perera12, Vincent Perlbarg16, Paolo Persona100, Wilco Peul101, Anna Piippo-Karjalainen102, Matti Pirinen95, Dana Pisica64, Horia Ples93, Suzanne Polinder64, Inigo Pomposo29, Jussi P. Posti 103, Louis Puybasset104, Andreea Radoi 105, Arminas Ragauskas106, Rahul Raj102, Malinka Rambadagalla107, Isabel Retel Helmrich64, Jonathan Rhodes108, Sylvia Richardson109, Sophie Richter47, Samuli Ripatti95, Saulius Rocka106, Cecilie Roe110, Olav Roise111,112, Jonathan Rosand113, Jeffrey V. Rosenfeld114, Christina Rosenlund115, Guy Rosenthal55, Rolf Rossaint77, Sandra Rossi100, Daniel Rueckert61, Martin Rusnák116, Juan Sahuquillo105, Oliver Sakowitz90, 117, Renan Sanchez Porras117, Janos Sandor118, Nadine Schäfer81, Silke Schmidt119, Herbert Schoechl120, Guus Schoonman121, Rico Frederik Schou122, Elisabeth Schwendenwein6, Charlie Sewalt64, Toril Skandsen123, 124 , Peter Smielewski26, Abayomi Sorinola125, Emmanuel Stamatakis47, Simon Stanworth39, Robert Stevens126, William Stewart127, Ewout W. Steyerberg64, 128, Nino Stocchetti129, Nina Sundström130, Riikka Takala131, Viktória Tamás125, Tomas Tamosuitis132, Mark Steven Taylor20, Braden Te Ao52, Olli Tenovu0103, Alice Theadom52, Matt Thomas87, Dick Tibboel133, Marjolein Timmers74, Christos Toliass134, Tony Trapani28, Cristina Maria Tudora93, Andreas Unterberg90, Peter

Vajkoczy 135, Shirley Vallance²⁸, Egils Valeinis⁶⁰, Zoltán Vámos⁵⁰, Mathieu van der Jagt¹³⁶, Gregory Van der Steen⁴³, Joukje van der Naalt⁷¹, Jeroen T.J.M. van Dijck ¹⁰¹, Thomas A. van Essen¹⁰¹, Wim Van Hecke¹³⁷, Caroline van Heugten¹³⁸, Dominique Van Praag¹³⁹, Ernest van Veen⁶⁴, Thijs Vande Vyvere¹³⁷, Roel P. J. van Wijk¹⁰¹, Alessia Vargiolu³², Emmanuel Vega⁸³, Kimberley Velt⁶⁴, Jan Verheyden¹³⁷, Paul M. Vespa¹⁴⁰, Anne Vik¹²³, ¹⁴¹, Rimantas Vilcinis¹³², Victor Volovici⁶⁷, Nicole von Steinbüchel³⁸, Daphne Voormolen⁶⁴, Petar Vulekovic⁴⁶, Kevin K.W. Wang¹⁴², Eveline Wiegers⁶⁴, Guy Williams⁴⁷, Lindsay Wilson⁶⁹, Stefan Winzeck⁴⁷, Stefan Wolf¹⁴³, Zihui Yang¹¹³, Peter Ylén¹⁴⁴, Alexander Younsi⁹⁰, Frederick A. Zeiler^{47,145}, Veronika Zelinkova²⁰, Agate Ziverte⁶⁰, Tommaso Zoerle²⁷

1 Department of Physiology and Pharmacology, Section of Perioperative Medicine and Intensive Care, Karolinska Institutet, Stockholm, Sweden

2 János Szentágothai Research Centre, University of Pécs, Pécs, Hungary

3 Division of Surgery and Clinical Neuroscience, Department of Physical Medicine and Rehabilitation, Oslo University Hospital and University of Oslo, Oslo, Norway

4 Department of Neurosurgery, University Hospital Northern Norway, Tromsø, Norway

5 Department of Physical Medicine and Rehabilitation, University Hospital Northern Norway, Tromsø, Norway

6 Trauma Surgery, Medical University Vienna, Vienna, Austria

7 Department of Anesthesiology & Intensive Care, University Hospital Nancy, Nancy, France

8 Raymond Poincare hospital, Assistance Publique – Hopitaux de Paris, Paris, France

9 Department of Anesthesiology & Intensive Care, S Raffaele University Hospital, Milan, Italy

10 Department of Neurosurgery, Radboud University Medical Center, Nijmegen, The Netherlands

- 11 Department of Neurosurgery, University of Szeged, Szeged, Hungary
- 12 International Projects Management, ARTTIC, Munchen, Germany
- 13 Department of Neurology, Neurological Intensive Care Unit, Medical University of Innsbruck, Innsbruck, Austria
- 14 Department of Neurosurgery & Anesthesia & intensive care medicine, Karolinska University Hospital, Stockholm, Sweden
- 15 NIHR Surgical Reconstruction and Microbiology Research Centre, Birmingham, UK
- 16 Anesthésie-Réanimation, Assistance Publique – Hôpitaux de Paris, Paris, France
- 17 Department of Anesthesia & ICU, AOU Città della Salute e della Scienza di Torino - Orthopedic and Trauma Center, Torino, Italy
- 18 Department of Neurology, Odense University Hospital, Odense, Denmark
- 19 BehaviourWorks Australia, Monash Sustainability Institute, Monash University, Victoria, Australia
- 20 Department of Public Health, Faculty of Health Sciences and Social Work, Trnava University, Trnava, Slovakia
- 21 Quesgen Systems Inc., Burlingame, California, USA
- 22 Australian & New Zealand Intensive Care Research Centre, Department of Epidemiology and Preventive Medicine, School of Public Health and Preventive Medicine, Monash University, Melbourne, Australia
- 23 Department of Surgery and Perioperative Science, Umeå University, Umeå, Sweden
- 24 Department of Neurosurgery, Medical School, University of Pécs, Hungary and Neurotrauma Research Group, János Szentágotthai Research Centre, University of Pécs, Hungary

25 Department of Medical Psychology, Universitätsklinikum Hamburg-Eppendorf, Hamburg, Germany

26 Brain Physics Lab, Division of Neurosurgery, Dept of Clinical Neurosciences, University of Cambridge, Addenbrooke's Hospital, Cambridge, UK

27 Neuro ICU, Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico, Milan, Italy

28 ANZIC Research Centre, Monash University, Department of Epidemiology and Preventive Medicine, Melbourne, Victoria, Australia

29 Department of Neurosurgery, Hospital of Cruces, Bilbao, Spain

30 NeuroIntensive Care, Niguarda Hospital, Milan, Italy

31 School of Medicine and Surgery, Università Milano Bicocca, Milano, Italy

32 NeuroIntensive Care, ASST di Monza, Monza, Italy

33 Department of Neurosurgery, Medical Faculty RWTH Aachen University, Aachen, Germany

34 Department of Anesthesiology and Intensive Care Medicine, University Hospital Bonn, Bonn, Germany

35 Department of Anesthesia & Neurointensive Care, Cambridge University Hospital NHS Foundation Trust, Cambridge, UK

36 School of Public Health & PM, Monash University and The Alfred Hospital, Melbourne, Victoria, Australia

37 Radiology/MRI department, MRC Cognition and Brain Sciences Unit, Cambridge, UK

38 Institute of Medical Psychology and Medical Sociology, Universitätsmedizin Göttingen, Göttingen, Germany

39 Oxford University Hospitals NHS Trust, Oxford, UK

40 Intensive Care Unit, CHU Poitiers, Poitiers, France

- 41 University of Manchester NIHR Biomedical Research Centre, Critical Care Directorate, Salford Royal Hospital NHS Foundation Trust, Salford, UK
- 42 Movement Science Group, Faculty of Health and Life Sciences, Oxford Brookes University, Oxford, UK
- 43 Department of Neurosurgery, Antwerp University Hospital and University of Antwerp, Edegem, Belgium
- 44 Department of Anesthesia & Intensive Care, Maggiore Della Carità Hospital, Novara, Italy
- 45 Department of Neurosurgery, University Hospitals Leuven, Leuven, Belgium
- 46 Department of Neurosurgery, Clinical centre of Vojvodina, Faculty of Medicine, University of Novi Sad, Novi Sad, Serbia
- 47 Division of Anaesthesia, University of Cambridge, Addenbrooke's Hospital, Cambridge, UK
- 48 Center for Stroke Research Berlin, Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany
- 49 Intensive Care Unit, CHR Citadelle, Liège, Belgium
- 50 Department of Anaesthesiology and Intensive Therapy, University of Pécs, Pécs, Hungary
- 51 Departments of Neurology, Clinical Neurophysiology and Neuroanesthesiology, Region Hovedstaden Rigshospitalet, Copenhagen, Denmark
- 52 National Institute for Stroke and Applied Neurosciences, Faculty of Health and Environmental Studies, Auckland University of Technology, Auckland, New Zealand
- 53 Department of Neurology, Erasmus MC, Rotterdam, the Netherlands

- 54 Department of Anesthesiology and Intensive care, University Hospital Northern Norway, Tromso, Norway
- 55 Department of Neurosurgery, Hadassah-hebrew University Medical center, Jerusalem, Israel
- 56 Fundación Instituto Valenciano de Neurorehabilitación (FIVAN), Valencia, Spain
- 57 Department of Neurosurgery, Shanghai Renji hospital, Shanghai Jiaotong University/school of medicine, Shanghai, China
- 58 Karolinska Institutet, INCF International Neuroinformatics Coordinating Facility, Stockholm, Sweden
- 59 Emergency Department, CHU, Liège, Belgium
- 60 Neurosurgery clinic, Pauls Stradins Clinical University Hospital, Riga, Latvia
- 61 Department of Computing, Imperial College London, London, UK
- 62 Department of Neurosurgery, Hospital Universitario 12 de Octubre, Madrid, Spain
- 63 Department of Anesthesia, Critical Care and Pain Medicine, Medical University of Vienna, Austria
- 64 Department of Public Health, Erasmus Medical Center-University Medical Center, Rotterdam, The Netherlands
- 65 College of Health and Medicine, Australian National University, Canberra, Australia
- 66 Department of Neurosurgery, Neurosciences Centre & JPN Apex trauma centre, All India Institute of Medical Sciences, New Delhi-110029, India
- 67 Department of Neurosurgery, Erasmus MC, Rotterdam, the Netherlands
- 68 Department of Neurosurgery, Oslo University Hospital, Oslo, Norway
- 69 Division of Psychology, University of Stirling, Stirling, UK

70 Division of Neurosurgery, Department of Clinical Neurosciences, Addenbrooke's Hospital & University of Cambridge, Cambridge, UK

71 Department of Neurology, University of Groningen, University Medical Center Groningen, Groningen, Netherlands

72 Neurointensive Care , Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK

73 Salford Royal Hospital NHS Foundation Trust Acute Research Delivery Team, Salford, UK

74 Department of Intensive Care and Department of Ethics and Philosophy of Medicine, Erasmus Medical Center, Rotterdam, The Netherlands

75 Department of Clinical Neuroscience, Neurosurgery, Umeå University, Umeå, Sweden

76 Hungarian Brain Research Program - Grant No. KTIA_13_NAP-A-II/8, University of Pécs, Pécs, Hungary

77 Department of Anaesthesiology, University Hospital of Aachen, Aachen, Germany

78 Cyclotron Research Center , University of Liège, Liège, Belgium

79 Centre for Urgent and Emergency Care Research (CURE), Health Services Research Section, School of Health and Related Research (SchARR), University of Sheffield, Sheffield, UK

80 Emergency Department, Salford Royal Hospital, Salford UK

81 Institute of Research in Operative Medicine (IFOM), Witten/Herdecke University, Cologne, Germany

82 VP Global Project Management CNS, ICON, Paris, France

83 Department of Anesthesiology-Intensive Care, Lille University Hospital, Lille, France

84 Department of Neurosurgery, Rambam Medical Center, Haifa, Israel

85 Department of Anesthesiology & Intensive Care, University Hospitals Southampton NHS Trust, Southampton, UK

86 Cologne-Merheim Medical Center (CMMC), Department of Traumatology, Orthopedic Surgery and Sportmedicine, Witten/Herdecke University, Cologne, Germany

87 Intensive Care Unit, Southmead Hospital, Bristol, Bristol, UK

88 Department of Neurological Surgery, University of California, San Francisco, California, USA

89 Department of Anesthesia & Intensive Care, M. Bufalini Hospital, Cesena, Italy

90 Department of Neurosurgery, University Hospital Heidelberg, Heidelberg, Germany

91 Department of Neurosurgery, The Walton centre NHS Foundation Trust, Liverpool, UK

92 Department of Medical Genetics, University of Pécs, Pécs, Hungary

93 Department of Neurosurgery, Emergency County Hospital Timisoara, Timisoara, Romania

94 School of Medical Sciences, Örebro University, Örebro, Sweden

95 Institute for Molecular Medicine Finland, University of Helsinki, Helsinki, Finland

96 Analytic and Translational Genetics Unit, Department of Medicine; Psychiatric & Neurodevelopmental Genetics Unit, Department of Psychiatry; Department of Neurology, Massachusetts General Hospital, Boston, MA, USA

97 Program in Medical and Population Genetics; The Stanley Center for Psychiatric Research, The Broad Institute of MIT and Harvard, Cambridge, MA, USA

98 Department of Radiology, University of Antwerp, Edegem, Belgium

99 Department of Anesthesiology & Intensive Care, University Hospital of Grenoble, Grenoble, France

100 Department of Anesthesia & Intensive Care, Azienda Ospedaliera Università di Padova, Padova, Italy

101 Dept. of Neurosurgery, Leiden University Medical Center, Leiden, The Netherlands and
Dept. of Neurosurgery, Medical Center Haaglanden, The Hague, The Netherlands

102 Department of Neurosurgery, Helsinki University Central Hospital

103 Division of Clinical Neurosciences, Department of Neurosurgery and Turku Brain Injury
Centre, Turku University Hospital and University of Turku, Turku, Finland

104 Department of Anesthesiology and Critical Care, Pitié -Salpêtrière Teaching Hospital,
Assistance Publique, Hôpitaux de Paris and University Pierre et Marie Curie, Paris, France

105 Neurotraumatology and Neurosurgery Research Unit (UNINN), Vall d'Hebron Research
Institute, Barcelona, Spain

106 Department of Neurosurgery, Kaunas University of technology and Vilnius University,
Vilnius, Lithuania

107 Department of Neurosurgery, Rezekne Hospital, Latvia

108 Department of Anaesthesia, Critical Care & Pain Medicine NHS Lothian & University of
Edinburg, Edinburgh, UK

109 Director, MRC Biostatistics Unit, Cambridge Institute of Public Health, Cambridge, UK

110 Department of Physical Medicine and Rehabilitation, Oslo University
Hospital/University of Oslo, Oslo, Norway

111 Division of Orthopedics, Oslo University Hospital, Oslo, Norway

112 Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway

113 Broad Institute, Cambridge MA Harvard Medical School, Boston MA, Massachusetts
General Hospital, Boston MA, USA

114 National Trauma Research Institute, The Alfred Hospital, Monash University,
Melbourne, Victoria, Australia

115 Department of Neurosurgery, Odense University Hospital, Odense, Denmark

- 116 International Neurotrauma Research Organisation, Vienna, Austria
- 117 Klinik für Neurochirurgie, Klinikum Ludwigsburg, Ludwigsburg, Germany
- 118 Division of Biostatistics and Epidemiology, Department of Preventive Medicine, University of Debrecen, Debrecen, Hungary
- 119 Department Health and Prevention, University Greifswald, Greifswald, Germany
- 120 Department of Anaesthesiology and Intensive Care, AUVA Trauma Hospital, Salzburg, Austria
- 121 Department of Neurology, Elisabeth-TweeSteden Ziekenhuis, Tilburg, the Netherlands
- 122 Department of Neuroanesthesia and Neurointensive Care, Odense University Hospital, Odense, Denmark
- 123 Department of Neuromedicine and Movement Science, Norwegian University of Science and Technology, NTNU, Trondheim, Norway
- 124 Department of Physical Medicine and Rehabilitation, St.Olavs Hospital, Trondheim University Hospital, Trondheim, Norway
- 125 Department of Neurosurgery, University of Pécs, Pécs, Hungary
- 126 Division of Neuroscience Critical Care, John Hopkins University School of Medicine, Baltimore, USA
- 127 Department of Neuropathology, Queen Elizabeth University Hospital and University of Glasgow, Glasgow, UK
- 128 Dept. of Department of Biomedical Data Sciences, Leiden University Medical Center, Leiden, The Netherlands
- 129 Department of Pathophysiology and Transplantation, Milan University, and Neuroscience ICU, Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico, Milano, Italy

130 Department of Radiation Sciences, Biomedical Engineering, Umeå University, Umeå, Sweden

131 Perioperative Services, Intensive Care Medicine and Pain Management, Turku University Hospital and University of Turku, Turku, Finland

132 Department of Neurosurgery, Kaunas University of Health Sciences, Kaunas, Lithuania

133 Intensive Care and Department of Pediatric Surgery, Erasmus Medical Center, Sophia Children's Hospital, Rotterdam, The Netherlands

134 Department of Neurosurgery, Kings college London, London, UK

135 Neurologie, Neurochirurgie und Psychiatrie, Charité – Universitätsmedizin Berlin, Berlin, Germany

136 Department of Intensive Care Adults, Erasmus MC– University Medical Center Rotterdam, Rotterdam, the Netherlands

137 icoMetrix NV, Leuven, Belgium

138 Movement Science Group, Faculty of Health and Life Sciences, Oxford Brookes University, Oxford, UK

139 Psychology Department, Antwerp University Hospital, Edegem, Belgium

140 Director of Neurocritical Care, University of California, Los Angeles, USA

141 Department of Neurosurgery, St.Olavs Hospital, Trondheim University Hospital, Trondheim, Norway

142 Department of Emergency Medicine, University of Florida, Gainesville, Florida, USA

143 Department of Neurosurgery, Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany

144 VTT Technical Research Centre, Tampere, Finland

145 Section of Neurosurgery, Department of Surgery, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, MB, Canada

REFERENCES

1. Carney N, Totten AM, O'Reilly C, et al. Guidelines for the Management of Severe Traumatic Brain Injury, Fourth Edition. *Neurosurgery* 2017;80(1):6-15, doi:10.1227/NEU.0000000000001432
2. Oddo M, Poole D, Helbok R, et al. Fluid therapy in neurointensive care patients: ESICM consensus and clinical practice recommendations. *Intensive Care Med* 2018;44(4):449-463, doi:10.1007/s00134-018-5086-z
3. Robba C, Citerio G. How I manage intracranial hypertension. *Crit Care* 2019;23(1):243, doi:10.1186/s13054-019-2529-z
4. Stocchetti N, Maas AI. Traumatic intracranial hypertension. *N Engl J Med* 2014;370(22):2121-30, doi:10.1056/NEJMra1208708
5. Hawryluk GWJ, Aguilera S, Buki A, et al. A management algorithm for patients with intracranial pressure monitoring: the Seattle International Severe Traumatic Brain Injury Consensus Conference (SIBICC). *Intensive Care Med* 2019;45(12):1783-1794, doi:10.1007/s00134-019-05805-9
6. Cook AM, Morgan Jones G, Hawryluk GWJ, et al. Guidelines for the Acute Treatment of Cerebral Edema in Neurocritical Care Patients. *Neurocrit Care* 2020;32(3):647-666, doi:10.1007/s12028-020-00959-7
7. Kamel H, Navi BB, Nakagawa K, et al. Hypertonic saline versus mannitol for the treatment of elevated intracranial pressure: a meta-analysis of randomized clinical trials. *Crit Care Med* 2011;39(3):554-9, doi:10.1097/CCM.0b013e318206b9be
8. Mortazavi MM, Romeo AK, Deep A, et al. Hypertonic saline for treating raised intracranial pressure: literature review with meta-analysis. *J Neurosurg* 2012;116(1):210-21, doi:10.3171/2011.7.JNS102142
9. Schwimmbeck F, Voellger B, Chappell D, et al. Hypertonic Saline Versus Mannitol for Traumatic Brain Injury: A Systematic Review and Meta-analysis With Trial Sequential Analysis. *J Neurosurg Anesthesiol* 2021;33(1):10-20, doi:10.1097/ANA.0000000000000644

10. Shi J, Tan L, Ye J, et al. Hypertonic saline and mannitol in patients with traumatic brain injury: A systematic and meta-analysis. *Medicine (Baltimore)* 2020;99(35):e21655, doi:10.1097/MD.00000000000021655
11. Gu J, Huang H, Huang Y, et al. Hypertonic saline or mannitol for treating elevated intracranial pressure in traumatic brain injury: a meta-analysis of randomized controlled trials. *Neurosurg Rev* 2019;42(2):499-509, doi:10.1007/s10143-018-0991-8
12. Miyoshi Y, Kondo Y, Suzuki H, et al. Effects of hypertonic saline versus mannitol in patients with traumatic brain injury in prehospital, emergency department, and intensive care unit settings: a systematic review and meta-analysis. *J Intensive Care* 2020;8(61), doi:10.1186/s40560-020-00476-x
13. Wakai A, McCabe A, Roberts I, et al. Mannitol for acute traumatic brain injury. *Cochrane Database Syst Rev* 2013;8):CD001049, doi:10.1002/14651858.CD001049.pub5
14. Rickard AC, Smith JE, Newell P, et al. Salt or sugar for your injured brain? A meta-analysis of randomised controlled trials of mannitol versus hypertonic sodium solutions to manage raised intracranial pressure in traumatic brain injury. *Emerg Med J* 2014;31(8):679-83, doi:10.1136/emered-2013-202679
15. Berger-Pelletier E, Emond M, Lauzier F, et al. Hypertonic saline in severe traumatic brain injury: a systematic review and meta-analysis of randomized controlled trials - ERRATUM. *CJEM* 2016;18(3):243, doi:10.1017/cem.2016.323
16. Burgess S, Abu-Laban RB, Slavik RS, et al. A Systematic Review of Randomized Controlled Trials Comparing Hypertonic Sodium Solutions and Mannitol for Traumatic Brain Injury: Implications for Emergency Department Management. *Ann Pharmacother* 2016;50(4):291-300, doi:10.1177/1060028016628893
17. Cnossen MC, Huijben JA, van der Jagt M, et al. Variation in monitoring and treatment policies for intracranial hypertension in traumatic brain injury: a survey in 66 neurotrauma centers participating in the CENTER-TBI study. *Crit Care* 2017;21(1):233, doi:10.1186/s13054-017-1816-9

18. Cnossen MC, Polinder S, Andriessen TM, et al. Causes and Consequences of Treatment Variation in Moderate and Severe Traumatic Brain Injury: A Multicenter Study. *Crit Care Med* 2017;45(4):660-669, doi:10.1097/CCM.0000000000002263
19. Maas AI, Menon DK, Steyerberg EW, et al. Collaborative European NeuroTrauma Effectiveness Research in Traumatic Brain Injury (CENTER-TBI): a prospective longitudinal observational study. *Neurosurgery* 2015;76(1):67-80, doi:10.1227/NEU.0000000000000575
20. Steyerberg EW, Wiegers E, Sewalt C, et al. Case-mix, care pathways, and outcomes in patients with traumatic brain injury in CENTER-TBI: a European prospective, multicentre, longitudinal, cohort study. *Lancet Neurol* 2019;18(10):923-934, doi:10.1016/S1474-4422(19)30232-7
21. Cnossen MC, Polinder S, Lingsma HF, et al. Variation in structure and process of care in traumatic brain injury: provider profiles of European neurotrauma centers participating in the CENTER-TBI Study. *Plos One* 2016;11(8):e0161367, doi:10.1371/journal.pone.0161367
22. Steyerberg EW, Mushkudiani N, Perel P, et al. Predicting outcome after traumatic brain injury: development and international validation of prognostic scores based on admission characteristics. *PLoS Med* 2008;5(8):e165; discussion e165, doi:10.1371/journal.pmed.0050165
23. Ceyisakar IE, van Leeuwen N, Steyerberg EW, et al. Instrumental variable analysis to estimate treatment effects: a simulation study showing potential benefits of conditioning on hospital. *BMC Med Res Methodol* 2022;22(1):121, doi:10.1186/s12874-022-01598-6
24. Dreyer NA, Velentgas P, Westrich K, et al. The GRACE checklist for rating the quality of observational studies of comparative effectiveness: a tale of hope and caution. *J Manag Care Spec Pharm* 2014;20(3):301-8, doi:10.18553/jmcp.2014.20.3.301
25. R Core Team. R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. 2018.

26. van Buuren S, Groothuis-Oudshoorn K. mice: Multivariate Imputation by Chained Equations in R. 2011 2011;45(3):67, doi:10.18637/jss.v045.i03
27. Kochanek PM, Adelson PD, Rosario BL, et al. Comparison of Intracranial Pressure Measurements Before and After Hypertonic Saline or Mannitol Treatment in Children With Severe Traumatic Brain Injury. *JAMA Netw Open* 2022;5(3):e220891, doi:10.1001/jamanetworkopen.2022.0891
28. Anstey JR, Taccone FS, Udy AA, et al. Early Osmotherapy in Severe Traumatic Brain Injury: An International Multicenter Study. *J Neurotrauma* 2020;37(1):178-184, doi:10.1089/neu.2019.6399
29. Poole D, Citerio G, Helbok R, et al. Evidence for Mannitol as an Effective Agent Against Intracranial Hypertension: An Individual Patient Data Meta-analysis. *Neurocritical care* 2020;32(1):252-261, doi:10.1007/s12028-019-00771-y
30. Badenes R, Hutton B, Citerio G, et al. Hyperosmolar therapy for acute brain injury: study protocol for an umbrella review of meta-analyses and an evidence mapping. *BMJ Open* 2020;10(2):e033913, doi:10.1136/bmjopen-2019-033913
31. Rowland MJ, Veenith T, Scomparin C, et al. Sugar or salt ("SOS"): A protocol for a UK multicentre randomised trial of mannitol and hypertonic saline in severe traumatic brain injury and intracranial hypertension. *J Intensive Care Soc* 0(0):1751143720901690, doi:10.1177/1751143720901690
32. Dorman HR, Sondheimer JH, Cadnapaphornchai P. Mannitol-induced acute renal failure. *Medicine (Baltimore)* 1990;69(3):153-9, doi:10.1097/00005792-199005000-00003
33. Stuart FP, Torres E, Fletcher R, et al. Effects of single, repeated and massive mannitol infusion in the dog: structural and functional changes in kidney and brain. *Ann Surg* 1970;172(2):190-204, doi:10.1097/0000658-197008000-00004
34. Manninen PH, Lam AM, Gelb AW, et al. The effect of high-dose mannitol on serum and urine electrolytes and osmolality in neurosurgical patients. *Can J Anaesth* 1987;34(5):442-6, doi:10.1007/BF03014345

35. Berger S, Schurer L, Hartl R, et al. Reduction of post-traumatic intracranial hypertension by hypertonic/hyperoncotic saline/dextran and hypertonic mannitol. *Neurosurgery* 1995;37(1):98-107; discussion 107-8, doi:10.1227/00006123-199507000-00015
36. Rosner MJ, Coley I. Cerebral perfusion pressure: a hemodynamic mechanism of mannitol and the postmannitol hemogram. *Neurosurgery* 1987;21(2):147-56, doi:10.1227/00006123-198708000-00003
37. van Hengel P, Nikken JJ, de Jong GM, et al. Mannitol-induced acute renal failure. *Neth J Med* 1997;50(1):21-4, doi:10.1016/s0300-2977(96)00060-5
38. Robba C, Banzato E, Rebori P, et al. Acute Kidney Injury in Traumatic Brain Injury Patients: Results From the Collaborative European NeuroTrauma Effectiveness Research in Traumatic Brain Injury Study. *Crit Care Med* 2021;49(1):112-126, doi:10.1097/CCM.0000000000004673

Table 1. Preference for HTS versus mannitol versus both: baseline characteristics*					
	HTS	Mannitol	Both	p-value	Missing (%)
n	287	149	66		
Day of first mannitol administration (median [IQR]) <i>HTS patient may have had mannitol after day 1</i>	5.00 [3.00, 6.00]	2.00 [1.00, 3.00]	1.00 [1.00, 2.00]	<0.001	48.6
Day of first HTS administration (median [IQR]) <i>Mannitol patients may have had HTS after day 1</i>	2.00 [1.00, 3.00]	3.00 [3.00, 6.00]	1.00 [1.00, 2.00]	<0.001	23.1
Patient-HTS sum score	100.00 [100.00, 100.00]	0.00 [0.00, 0.00]	50.00 [50.00, 65.62]	<0.001	0.0
Patient characteristics					
Age (median [IQR])	42.00 [26.00, 57.50]	49.00 [35.00, 67.00]	43.00 [30.00, 61.00]	0.004	0.0
Male (%)	220 (76.7)	112 (75.2)	43 (65.2)	0.151	0.0

ASAPS class (%)				0.535	4.0
1	170 (61.4)	85 (59.9)	36 (57.1)		
2	77 (27.8)	47 (33.1)	22 (34.9)		
3	30 (10.8)	10 (7.0)	5 (7.9)		
Region (%)				<0.001	0.0
Baltic States	14 (4.9)	2 (1.3)	5 (7.6)		
Eastern Europe	1 (0.3)	6 (4.0)	0 (0.0)		
Northern Europe	72 (25.1)	11 (7.4)	3 (4.5)		
Southern Europe	50 (17.4)	41 (27.5)	20 (30.3)		
United Kingdom	68 (23.7)	27 (18.1)	11 (16.7)		
Western Europe	82 (28.6)	62 (41.6)	27 (40.9)		
Baseline characteristics					
GCS motor score at baseline (%)				0.255	2.2
1	125 (44.6)	71 (48.3)	28 (43.8)		
2	11 (3.9)	8 (5.4)	5 (7.8)		
3	27 (9.6)	4 (2.7)	7 (10.9)		
4	24 (8.6)	13 (8.8)	5 (7.8)		
5	61 (21.8)	26 (17.7)	11 (17.2)		
6	32 (11.4)	25 (17.0)	8 (12.5)		

Reactive pupils at baseline (%)				0.185	6.6
Both reactive	192 (71.6)	108 (77.1)	44 (72.1)		
One reactive	36 (13.4)	10 (7.1)	4 (6.6)		
Both unreactive	40 (14.9)	22 (15.7)	13 (21.3)		
Total ISS (median [IQR])	33.00 [25.00, 43.00]	34.00 [25.00, 45.00]	34.00 [25.00, 50.00]	0.297	0.0
Major extracranial injury (%)	153 (53.3)	87 (58.4)	43 (65.2)	0.182	0.0
CT characteristics					
Marshall CT Classification (%)				<0.001	11.4
I	6 (2.3)	0 (0.0)	0 (0.0)		
II	77 (30.1)	29 (22.3)	7 (11.9)		
III	34 (13.3)	16 (12.3)	9 (15.3)		
IV	5 (2.0)	1 (0.8)	6 (10.2)		
V/VI	134 (52.3)	84 (64.6)	37 (62.7)		
ICP and fluid balance					
ICP monitoring (%)	254 (88.5)	123 (82.6)	61 (92.4)	0.084	0.0
Mean ICP during hospital stay (median [IQR])	13.22 [10.16, 16.23]	13.29 [10.89, 16.59]	15.33 [12.52, 20.72]	0.001	14.5
Mean ICP before receiving an agent	13.68	13.51	16.11	0.002	20.1

(median [IQR])	[9.83, 16.71]	[11.05, 16.89]	[12.82, 22.71]		
Fluid balance during hospital stay	305.50 [-161.50, 843.00]	433.50 [24.25, 1142.75]	595.75 [42.12, 1116.00]	0.058	12.5
ICP lowering therapies before hyperosmolar therapy					
Metabolic suppression using high dose barbiturates or propofol (%)	74 (26.1)	29 (20.1)	20 (30.8)	0.208	1.8
Neuromuscular blockade (paralysis) (%)	73 (25.7)	37 (25.7)	25 (38.5)	0.099	1.8
Intensive hypocapnia for ICP control [PaCO ₂ < 4.0 kPa (30 mmHg)] (%)	9 (3.2)	3 (2.1)	6 (9.2)	0.031	2.0
Hypothermia below 35°C (%)	14 (4.9)	7 (4.9)	4 (6.2)	0.912	1.8
DC before hyperosmolar therapy (%)	30 (10.6)	32 (22.2)	18 (27.7)	<0.001	1.8
Maximum TIL (median [IQR])	9.00 [6.00, 13.00]	8.00 [6.00, 13.00]	14.00 [9.00, 18.00]	<0.001	0.0
ICP lowering therapies during the whole ICU stay					
Metabolic suppression using high dose barbiturates or propofol (%)	96 (33.4)	48 (32.2)	23 (34.8)	0.926	0.0
Neuromuscular blockade (paralysis) (%)	105 (36.6)	47 (31.5)	28 (42.4)	0.285	0.0

Intensive hypocapnia for ICP control [PaCO ₂ < 4.0 kPa (30 mmHg)] (%)	17 (5.9)	4 (2.7)	8 (12.1)	0.024	0.2
Hypothermia below 35°C (%)	22 (7.7)	13 (8.7)	7 (10.6)	0.726	0.0
DC (%)	47 (16.4)	41 (27.5)	20 (30.3)	0.005	0.0
Maximum TIL (median [IQR])	11.00 [8.00, 14.00]	11.00 [8.00, 15.00]	15.00 [12.25, 19.00]	<0.001	0.0
Outcomes					
Probability of mortality using the IMPACT core score (median [IQR])	0.29 [0.19, 0.48]	0.35 [0.19, 0.55]	0.29 [0.19, 0.55]	0.361	8.4
Probability of unfavourable outcome using the IMPACT core score (median [IQR])	0.54 [0.40, 0.74]	0.62 [0.40, 0.80]	0.54 [0.40, 0.80]	0.361	8.4
ICU mortality (%)	58 (20.2)	28 (19.3)	24 (36.4)	0.011	0.8
GOSE after 6 months (%)				0.092	10.6
Dead	74 (29.1)	43 (32.3)	29 (46.8)		
Vegetative state/ Lower severe disability	54 (21.3)	30 (22.6)	14 (22.6)		
Upper severe disability	26 (10.2)	9 (6.8)	5 (8.1)		
Lower moderate disability	41 (16.1)	13 (9.8)	3 (4.8)		
Upper moderate disability –	25 (9.8)	12 (9.0)	3 (4.8)		

some disability but can potentially return to some form of employment					
Lower good recovery – minor physical or mental defect	17 (6.7)	17 (12.8)	3 (4.8)		
Upper good recovery – full recovery	17 (6.7)	9 (6.8)	5 (8.1)		

Abbreviations: ASAPS = American Society of Anesthesiologists Physical Status; CT = Computed tomography; DC = decompressive craniectomy; GCS = Glasgow coma scale; GOSE = Glasgow outcome scale extended; HTS = hypertonic saline; ICP = intracranial pressure; ICU = intensive care unit; IQR = interquartile range; ISS = injury severity score; TIL = therapy intensity level

*Mannitol, HTS or both, was defined as the first received HOA. As for both, this means that a patient received mannitol and HTS on the same day.

Table 2. Unadjusted and adjusted OR and CI for ICU mortality						
Variables	Unadjusted OR	CI	Adjusted OR for baseline characteristics	CI	Adjusted OR for baseline and treatment characteristics	CI
Patient-level						
HTS (ref)	1		1		1	
Mannitol	0.94	0.57 – 1.56	0.94	0.51 – 1.71	0.98	0.44 – 2.20
Both	2.26	1.26 – 4.03	2.56	1.23 – 5.32	1.81	0.65 – 5.00
Center-level (cut-off at 66%)						
HTS (ref)	1		1		1	
Mannitol	1.19	0.64 – 2.23	1.13	0.53 – 2.40	0.62	0.21 – 1.88
Both	1.77	1.11 – 2.84	1.64	0.92 – 2.90	1.35	0.62 – 2.94
Center-level (cut-off at 75%)						
HTS (ref)	1		1		1	
Mannitol	1.19	0.59 – 2.38	1.28	0.56 – 2.94	0.62	0.21 – 1.88
Both	1.41	0.87 – 2.29	1.54	0.85 – 2.81	1.35	0.62 – 2.94

Management-level						
HTS (ref)	1		1		1	
Mannitol	1.76	0.85 – 3.63	1.78	0.72 – 4.43	1.44	0.40 – 5.20
Both	2.14	1.27 – 3.62	1.93	1.03 – 3.60	1.51	0.64 – 3.60
Patient-HTS sum score¹						
Sum HTS, patient-level	0.999	0.994 – 1.004	0.999	0.992 – 1.005	0.998	0.989 – 1.006
Center-HTS sum score²						
Sum HTS, center-level	0.997	0.990 – 1.004	0.998	0.990 – 1.006	1.000	0.989 – 1.012

Odds ratios above 1 indicate **worse** outcome

*Baseline characteristics: age, GCS motor score, pupillary reactivity, MEI, and Marshall CT classification

**Treatment characteristics: mean ICP before receiving a HOA, mean TIL before receiving a HOA, and median daily fluid balance during the whole ICU stay

Abbreviations: CI = confidence interval; GCS = glasgow coma scale; HOA = hyperosmolar agent; HTS = hypertonic saline; ICU = intensive care unit; MEI = major extracranial injury; OR = odds ratio; ref = reference; TIL = therapy intensity level

¹ For example, if a patient received only HTS for 5 days, only mannitol for 3 days, and mannitol and HTS (both) for 2 days, this patient would get a sum score of $(5+0+2)/(5+3+4) = 0.6$. Or, if a patient received only HTS for 1 day, only mannitol for 9 days, and mannitol and HTS for 0 days, this patient would get a sum score of $(1+0+0)/(1+9+0) = 0.1$.

² For example: a center included 2 patients. One patient has a patient-HTS sum score of 0.7, the other of 0.1. The sum score on center level is calculated as follows: $(0.7 + 0.1) / 2 = 0.4$. Thus, all patients in that center will have a score of 0.4 for the analyses.

Table 3. Unadjusted and adjusted OR and CI for 6-month GOSE						
Variables	Unadjusted OR	CI	Adjusted OR for baseline characteristics*	CI	Adjusted OR for baseline and treatment characteristics**	CI
Patient-level						
HTS (ref)	1		1		1	
Mannitol	0.97	0.67 – 1.41	1.03	0.65 – 1.64	0.91	0.53 – 1.58
Both	0.51	0.30 – 0.85	0.48	0.25 – 0.92	0.64	0.30 – 1.37
Center-level (cut-off at 66%)						
HTS (ref)	1		1		1	
Mannitol	0.75	0.47 – 1.18	0.95	0.55 – 1.64	1.46	0.46 – 4.60
Both	0.54	0.37 – 0.78	0.59	0.38 – 0.90	0.71	0.26 – 1.96
Center-level (cut-off at 75%)						
HTS (ref)	1		1		1	
Mannitol	0.80	0.47 – 1.36	0.91	0.48 – 1.71	1.45	0.67 – 3.12
Both	0.66	0.46 – 0.95	0.65	0.41 – 1.02	0.63	0.38 – 1.05
Management-level						
HTS (ref)	1		1		1	
Mannitol	0.73	0.43 – 1.25	1.01	0.53 – 1.93	1.36	0.53 – 3.48

Both	0.49	0.34 – 0.72	0.70	0.45 – 1.08	0.83	0.46 – 1.51
Patient-HTS sum score¹						
Sum HTS	1.001	0.996 – 1.005	1.000	0.995 – 1.005	1.001	0.995 – 1.007
Center-HTS sum score²						
Sum HTS	1.003	0.998 – 1.008	1.000	0.993 – 1.007	0.999	0.990 – 1.007

Odds ratios above 1 indicate **better** outcome

*Baseline characteristics: age, GCS motor score, pupillary reactivity, MEI, and Marshall CT classification

**Treatment characteristics: mean ICP before receiving a HOA, mean TIL before receiving a HOA, and median daily fluid balance during the whole ICU stay

Abbreviations: CI = confidence interval; GCS = glasgow coma scale; HOA = hyperosmolar agent; HTS = hypertonic saline; ICU = intensive care unit; MEI = major extracranial injury; OR = odds ratio; ref = reference; TIL = therapy intensity level

¹ For example, if a patient received only HTS for 5 days, only mannitol for 3 days, and mannitol and HTS (both) for 2 days, this patient would get a sum score of $(5+0+2)/(5+3+4) = 0.6$. Or, if a patient received only HTS for 1 day, only mannitol for 9 days, and mannitol and HTS for 0 days, this patient would get a sum score of $(1+0+0)/(1+9+0) = 0.1$.

² For example: a center included 2 patients. One patient has a patient-HTS sum score of 0.7, the other of 0.1. The sum score on center level is calculated as follows: $(0.7 + 0.1) / 2 = 0.4$. Thus, all patients in that center will have a score of 0.4 for the analyses.




Figure 1. Percentage of patients per stratum (HTS, mannitol or both*)